Get the Stockscreener App
105.51
0.35%
0.49
Boston Scientific Corp stock is traded at $105.51, with a volume of 2.59M.
It is up +0.35% in the last 24 hours and up +14.57% over the past month.
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
See More
Previous Close:
$105.02
Open:
$104.75
24h Volume:
2.59M
Relative Volume:
0.50
Market Cap:
$154.78B
Revenue:
$15.91B
Net Income/Loss:
$1.79B
P/E Ratio:
87.20
EPS:
1.21
Net Cash Flow:
$1.89B
1W Performance:
+2.96%
1M Performance:
+14.57%
6M Performance:
+42.84%
1Y Performance:
+61.57%
1-Day Range:
$104.29
$105.81
1-Week Range:
$100.70
$107.17
52-Week Range:
$64.39
$107.17
Boston Scientific Corp Stock (BSX) Company Profile
Name
Boston Scientific Corp
Sector
Industry
Phone
508-683-4000
Address
300 BOSTON SCIENTIFIC WAY, MARLBOROUGH, MA
Compare BSX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BSX
Boston Scientific Corp
|
105.52 | 154.78B | 15.91B | 1.79B | 1.89B | 1.21 |
|
ABT
Abbott Laboratories
|
129.16 | 222.39B | 41.95B | 13.40B | 6.49B | 7.65 |
|
SYK
Stryker Corp
|
391.90 | 150.99B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
90.02 | 116.46B | 33.00B | 4.29B | 5.50B | 3.27 |
|
EW
Edwards Lifesciences Corp
|
71.21 | 41.87B | 6.60B | 4.16B | 490.10M | 6.93 |
Boston Scientific Corp Stock (BSX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-10-25 | Upgrade | Deutsche Bank | Hold → Buy |
| Oct-18-24 | Downgrade | Needham | Buy → Hold |
| May-30-24 | Initiated | Goldman | Buy |
| Feb-01-24 | Upgrade | Mizuho | Neutral → Buy |
| Jul-19-23 | Initiated | Robert W. Baird | Outperform |
| Jun-30-23 | Initiated | CL King | Buy |
| May-30-23 | Resumed | Morgan Stanley | Overweight |
| Mar-29-23 | Initiated | UBS | Buy |
| Dec-22-22 | Initiated | Mizuho | Neutral |
| Dec-20-22 | Resumed | Citigroup | Buy |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Buy |
| Jul-06-22 | Initiated | Wolfe Research | Outperform |
| May-27-22 | Upgrade | Needham | Hold → Buy |
| Apr-13-22 | Resumed | Truist | Buy |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| May-26-21 | Downgrade | Needham | Buy → Hold |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Overweight |
| Sep-17-20 | Initiated | Truist | Buy |
| Sep-11-20 | Initiated | Wolfe Research | Peer Perform |
| Apr-22-20 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Apr-01-20 | Upgrade | Goldman | Neutral → Buy |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Neutral |
| Feb-06-20 | Resumed | BTIG Research | Buy |
| Dec-30-19 | Reiterated | Cowen | Outperform |
| Dec-19-19 | Downgrade | Needham | Strong Buy → Buy |
| Sep-05-19 | Resumed | JP Morgan | Overweight |
| Sep-03-19 | Resumed | Barclays | Overweight |
| May-13-19 | Upgrade | Evercore ISI | In-line → Outperform |
| Nov-28-18 | Initiated | UBS | Buy |
| Oct-16-18 | Initiated | Barclays | Overweight |
| Oct-02-18 | Reiterated | Morgan Stanley | Overweight |
| Sep-07-18 | Reiterated | Needham | Strong Buy |
| Sep-04-18 | Upgrade | Jefferies | Hold → Buy |
| Jul-06-18 | Reiterated | Needham | Strong Buy |
| Jun-27-18 | Initiated | Bernstein | Outperform |
| Apr-26-18 | Reiterated | Needham | Strong Buy |
View All
Boston Scientific Corp Stock (BSX) Latest News
Boston Scientific (NYSE:BSX) Announces Earnings Results - MarketBeat
Farapulse boosts Boston Scientific’s Q4 electrophysiology sales by 172% - Medical Device Network
Boston Scientific (NYSE:BSX) Releases Quarterly Earnings Results - MarketBeat
March 28th Options Now Available For Boston Scientific (BSX) - Nasdaq
Boston Scientific (NYSE:BSX) Hits New 1-Year High Following Better-Than-Expected Earnings - MarketBeat
RBC Capital raises Boston Scientific price target to $116 - Investing.com India
Boston Scientific Corporation (NYSE:BSX) Q4 2024 Earnings Call Transcript - MSN
Truist lifts Boston Scientific stock target to $120, maintains Buy - Investing.com
Mizuho raises Boston Scientific target to $130, maintains Outperform - Investing.com
Canaccord raises Boston Scientific stock target to $117 - Investing.com
Boston Scientific Co. (NYSE:BSX) Shares Sold by Long Run Wealth Advisors LLC - MarketBeat
Boston Scientific sales increase 22.4% to USD 4.561 billion in Q4 2024 - Medical Buyer
Boston Scientific Corp (BSX) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Strong ... - Yahoo Finance
Boston Scientific Shines with Strong Earnings Performance - TipRanks
Boston Sci’s Farapulse tops $1B in 2024, bright prospects for 2025 - BioWorld Online
Boston Scientific remains bullish despite tariffs, with sales buoyed by Minnesota tech - MSN
How Boston Sci Leaned On Its New Heart Device For A Fourth-Quarter Beat - Yahoo! Voices
New Heart Device Pumps Earnings Beat For This Stock - Investor's Business Daily
Arthur C. Butcher Sells 17,313 Shares of Boston Scientific Co. (NYSE:BSX) Stock - MarketBeat
Boston Scientific expects double-digit sales growth in 2025 following Street-beating Q4 - Mass Device
Sector Update: Health Care -February 05, 2025 at 01:33 pm EST - Marketscreener.com
Boston Scientific targets 12%-14% EPS growth for 2025 with strong FARAPULSE and WATCHMAN momentum - MSN
Boston Scientific announces results for fourth quarter and full year 2024 - BioSpace
Boston Scientific closes its year of PFA on a high note - MedTech Dive
Boston Scientific Beats Quarterly Revenue Views; 2025 Outlook Implies Deceleration - Marketscreener.com
Boston Scientific clocks over $1B in Farapulse revenue for the afib therapy's first year - Fierce Biotech
Boston Scientific Projects Rosy 2025 Profits With Device Demand Surge - Finimize
Boston Scientific : Interested in our Q4 2024 earnings -February 05, 2025 at 09:58 am EST - Marketscreener.com
Boston Scientific Corporation Provides Earnings Guidance for the First Quarter and Full Year of 2025 - Marketscreener.com
Boston Scientific (BSX) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
Boston Scientific sees higher-than-expected 2025 profit on strong demand - MSN
Boston Scientific Beats Its Own Fourth-Quarter Guidance On Cardiovascular Strength - Yahoo! Voices
Boston Scientific Corporation Reports Earnings Results for the Fourth Quarter Ended December 31, 2024 - Marketscreener.com
Boston Scientific Clocks 22% Jump In Q4 Sales On Strong Heart Devices, Profit And Guidance Exceeds Expectations - Benzinga
Boston Scientific Q4 2024 Earnings Preview - MSN
Boston Scientific (NYSE:BSX) Updates Q1 2025 Earnings Guidance - MarketBeat
Boston Scientific (NYSE:BSX) Releases FY 2025 Earnings Guidance - MarketBeat
Boston Scientific Co. (NYSE:BSX) Shares Acquired by Jackson Wealth Management LLC - MarketBeat
Boston Scientific (BSX) Surpasses Q4 Earnings and Revenue Estimates - Yahoo Finance Australia
Boston Scientific earnings beat by $0.04, revenue topped estimates - Investing.com
Boston Scientific Corp (BSX) Q4 2024 Earnings: Revenue Surpasses - GuruFocus.com
Boston Scientific 4Q Profit Up on Strong Cardio Device Sales - AllSides
Boston Scientific: Q4 Earnings Snapshot - The Washington Post
Boston Scientific reports above-consensus Q4 results, provides outlook - Investing.com
Boston Scientific: Q4 Earnings Snapshot -February 05, 2025 at 06:50 am EST - Marketscreener.com
Boston Scientific Corporation’s Q4 2024 Net Sales Surge by 22.4%, Exceeding Expectations - The Tokenist
Boston Scientific (NYSE:BSX) Reports Bullish Q4, Guides for Strong Sales Next Quarter - Yahoo Finance
Yousif Capital Management LLC Has $20.76 Million Stock Position in Boston Scientific Co. (NYSE:BSX) - MarketBeat
Boston Scientific: Q4 Earnings Snapshot | National Business News | voiceofalexandria.com - Voice Of Alexandria
Boston Scientific Reports Results For Q4 And FY 2024 -February 05, 2025 at 06:47 am EST - Marketscreener.com
Mather Group LLC. Has $807,000 Stock Position in Boston Scientific Co. (NYSE:BSX) - MarketBeat
Boston Scientific Corp Stock (BSX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.00%
0.70%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):